Skip to main content
. 2013 Nov 19;1(1):2–14. doi: 10.1002/acn3.19

Figure 8.

Figure 8

Safety in combination with atorvastatin and in permanent ischemia. (A) Daily atorvastatin treatment for 2 weeks was followed by vehicle or KD025 administration (arrows) starting 1 h after fMCAO and continuing until sacrifice for tissue outcome assessment at 48 h (four doses). (B) Infarct volumes (indirect method) after vehicle or KD025 (200 mg/kg) in combination with atorvastatin (n = 6 each). Boxes, median and interquartile range; whiskers, min–max; +, mean. Unpaired t-test. (C) Timeline shows vehicle or KD025 administration (arrows) via oral gavage starting 1 h after permanent fMCAO and continuing until tissue outcome assessment at 24 h (two doses). (D) Infarct volumes (indirect method) in vehicle or KD025 (200 mg/kg) groups after permanent fMCAO (n = 10 and 9, respectively; P = 0.19). Boxes, median, and interquartile range; whiskers, min–max; +, mean. Unpaired t-test.